Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C

NCT00227435 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00227435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00227435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2003
Completion date
July 31, 2004
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c